A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to see if TTI-622 and daratumumab hyaluronidase-fihj are safe for people with multiple myeloma. They are looking for the best amount of TTI-622 that doesn't have many side effects when combined with daratumumab hyaluronidase-fihj. If they find a safe dose, they will test it on more people to see if it helps treat multiple myeloma. The researchers think combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj could be a good way to treat this disease.
This study wants to see if TTI-622 and daratumumab hyaluronidase-fihj are safe for people with multiple myeloma. They are looking for the best amount of TTI-622 that doesn't have many side effects when combined with daratumumab hyaluronidase-fihj. If they find a safe dose, they will test it on more people to see if it helps treat multiple myeloma. The researchers think combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj could be a good way to treat this disease.
*Third Opinion AI Generated Synopsis
Trial Summary
This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each study drug, they will further test the combination TTI-622 + daratumumab hyaluronidase-fihj) in new participants to find out if the combinations are effective in treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may be an effective treatment approach.
This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each study drug, they will further test the combination TTI-622 + daratumumab hyaluronidase-fihj) in new participants to find out if the combinations are effective in treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may be an effective treatment approach.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
